US Biomarkers Market size and share is currently valued at USD 25.92 billion in 2024 and is anticipated to generate an estimated revenue of USD 106.03 Billion by 2034, according to the latest study by Polaris Market Research. Besides, the report notes that the market exhibits a robust 15.16% Compound Annual Growth Rate (CAGR) over the forecasted timeframe, 2025 – 2034

Market’s Growth Drivers
Several interlinked factors are driving the growth of the biomarkers sector in the United States:

1. Increasing Prevalence of Chronic and Complex Diseases
   The U.S. continues to face high incidence of cancers, cardiovascular diseases, neurological diseases (such as Alzheimer’s), and immunological disorders. Biomarkers play an increasingly critical role in early detection, diagnosis, monitoring therapeutic response and prognostication.
   For example, estimates for 2025 suggest over 2 041 910 new cancer cases in the U.S., reinforcing demand for biomarker‑driven oncology diagnostics and companion therapies. 
2. Growth of Precision Medicine and Companion Diagnostics
   As therapies become more targeted and personalized, biomarkers are essential for stratifying patients, predicting response, monitoring minimal residual disease and tailoring treatment regimens. For instance, the U.S. personalized‑medicine biomarkers market was valued at around US$ 9.85 billion in 2024 and is projected to reach roughly US$ 21.67 billion by 2030 (CAGR ~14 %). 
3. Technological Advancements in Genomics, Proteomics, Metabolomics
   Advances in next‑generation sequencing (NGS), high‑throughput proteomics, metabolomic profiling and bioinformatics have improved biomarker discovery, validation and commercialization. The genomics research area dominates within the U.S. biomarkers space, supported by widespread adoption of gene panels and molecular diagnostics. 
4. Strong Regulatory & Institutional Environment
   The U.S. regulatory framework, including initiatives such as the Precision Medicine Initiative and the U.S. Food & Drug Administration’s Fit‑For‑Purpose (FFP) drug development tools, alongside well‑funded academic institutions, make the U.S. a leading environment for biomarker R&D and adoption.
5. Rising Healthcare Expenditure & Investment in Diagnostics
   With increases in healthcare spending and demand for advanced diagnostics, laboratories, biobanking facilities, and biotech companies are investing heavily in biomarker testing, implementation and commercialization across the U.S.

Key Trends
Several overarching trends are shaping the U.S. biomarkers market, influencing how the market evolves and where investment is heading:

1. Expansion of Non‑Invasive & Liquid Biopsy Biomarkers
   Blood‑based biomarkers, cell‑free DNA, circulating tumor DNA (ctDNA), and minimal residual disease (MRD) testing are rapidly gaining traction. For example, the U.S. blood‑based biomarkers market was valued at USD 3.0499 billion in 2024 and expected to grow to USD 4.393 billion by 2030 (CAGR ~6.8 %). 
2. Growth in Neurological and Rare Disease Biomarkers
   While oncology remains the dominant indication, neurological disorders (e.g., Alzheimer’s, Parkinson’s) are emerging as high‑growth areas. The U.S. biomarkers market research indicated the neurological disorders segment will witness the fastest CAGR during forecast years. 
3. Integration with Artificial Intelligence (AI), Big Data & Predictive Analytics
   AI and machine learning are increasingly used to analyze biomarker data, detect patterns, predict outcomes and optimize diagnostics. These technologies enable improved accuracy, better stratification and faster validation of biomarker candidates.
4. Shift Toward Preventive and Predictive Healthcare Models
   With emphasis on value‑based care and early intervention, biomarkers are being used not just for treatment decisions but also risk‑assessment, screening and preventive health monitoring. The U.S. predictive biomarkers market was valued at USD 9.5329 billion in 2024 and is projected to reach USD 24.363 billion by 2030 (CAGR ~17.6 %). 
5. Rise of Companion Diagnostics & Biomarker‑Guided Therapies
   Many new drug approvals in oncology and immunology now require biomarker testing (e.g., PD‑L1, BRCA, HER2). This has increased demand for diagnostics platforms tied to specific therapies and has established biomarkers as a strategic asset within pharmaceutical pipelines.

Research Scope
The research scope within the U.S. biomarkers market includes multiple dimensions: discovery, validation, commercialization, regulatory pathways, and application expansion. Some key research areas include:

• Discovery and Validation of Novel Biomarkers: Investigations into genomics, proteomics, metabolomics and epigenetics to identify new markers for disease initiation, progression or therapeutic response.
• Technology Innovation: Enhancing assay sensitivity, multiplexing, automation, sample throughput, point‑of‑care diagnostics, and non‑invasive collection methods (e.g., liquid biopsies, saliva, tissue‑free biomarkers).
• Clinical Utility & Real‑World Evidence: Demonstrating clinical validity and utility of biomarkers across indications, including in large‑scale cohorts, biobanks and longitudinal monitoring.
• Regulatory & Reimbursement Strategy: Navigating FDA pathways, ensuring analytic and clinical validation, aligning biomarker diagnostics with reimbursement frameworks, and establishing standardized protocols.
• Market Adoption & Implementation Research: Understanding barriers to adoption (e.g., cost, workflow integration, clinician education), optimizing laboratory infrastructure, and scaling biomarker usage in routine care.
• Cross‑discipline & Multi‑Modal Omics Integration: Combining biomarker data with imaging, digital health tools, wearable devices and AI analytics to enable holistic patient monitoring and personalized treatment strategies.

𝐌𝐚𝐣𝐨𝐫 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬:

• 23andMe, Inc.
• Abbott Laboratories
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Charles River Laboratories International, Inc.
• Exact Sciences Corporation
• Guardant Health, Inc.
• Hologic, Inc.
• Illumina, Inc.
• Johnson & Johnson Services, Inc.
• Laboratory Corporation of America Holdings
• Meso Scale Diagnostics, LLC
• PerkinElmer, Inc. (Revvity, Inc.)
• Quest Diagnostics Incorporated
• Thermo Fisher Scientific, Inc.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞:  https://www.polarismarketresearch.com/industry-analysis/us-biomarkers-market

Market Segmentation
To understand the U.S. biomarkers market structure, segmentation can be analysed by type, technology/research area, application/indication, end‑use and region within the country.

By Type

• Safety Biomarkers: Indicators used primarily in drug development to monitor adverse effects, toxicity and safety profiles.
• Efficacy Biomarkers: Used to measure therapeutic effect, treatment response or disease progression. The ‘efficacy’ type segment was identified as the largest revenue‑generating type in 2023 for the U.S. market.
• Validation Biomarkers: Used to validate drug targets, diagnostic tests or research findings, often in translational research settings.

By Research Area / Technology

• Genomics: Dominant segment in 2024, includes gene expression, mutation profiling, NGS, transcriptomics.
• Proteomics: Rapidly growing, especially for biomarker discovery in neurological and immunological disorders.
• Metabolomics, Epigenetics & Other Omics: Additional emerging areas capturing interest for comprehensive biomarker panels.

By Disease Indication / Application

• Oncology: Continues to hold the largest share, driven by high incidence, need for early detection, companion diagnostics and targeted therapies. 
• Cardiovascular Diseases: Important growth area given chronic prevalence and preventive screening opportunities.
• Neurological Disorders: Fast‑growing due to Alzheimer’s, Parkinson’s and demand for early diagnostic biomarkers.
• Immunological/Autoimmune Diseases: Emerging segment with increasing R&D focus.
• Other Indications: Infectious diseases, metabolic disorders, rare diseases and personalized wellness.

By Application / End‑Use

• Clinical Diagnostics: Routine biomarker tests for disease detection, risk stratification, monitoring therapy. The largest revenue share for diagnostic applications in 2024. 
• Drug Discovery & Development: Biomarkers used by pharmaceutical and biotech firms for target identification, patient selection and monitoring in clinical trials.
• Personalized Medicine: Biomarker‑guided treatment selection, companion diagnostics, monitoring outcomes. Expected to be fastest growing application. 
• Research Laboratories & Biobanks: Academic, government and commercial labs generating new biomarker data, samples and validating tools.

By Region (U.S. Internal Geography)
While the U.S. is considered as a single national market, regional dynamics influence adoption: the Northeast (Boston, Cambridge, New York) has high concentration of biotech, diagnostics and academic research institutions; the West Coast (California, Silicon Valley) is strong in tech‑driven biomarker platforms; other hubs in the Midwest and South are developing. According to one report, the Northeast leads in the U.S. biomarkers market due to partnerships and concentration of research entities.

Conclusion
The U.S. biomarkers market stands at a pivotal inflection point—propelled by advances in precision medicine, escalating chronic disease burdens and rapid technological innovation. With strong growth drivers in place and emerging trends pointing toward non‑invasive diagnostics, deeper integration with AI and data analytics, and a shift toward preventive‑rather than reactive‑care models, the future looks bright. Research and commercialization pathways continue to evolve, with increasing emphasis on real‑world evidence, regulatory frameworks and reimbursement integration.

For stakeholders—be it diagnostics companies, biotech firms, academic researchers or investors—the essential task is to align product development with clinical utility, ensure market access and stay ahead of disruption. Ultimately, biomarkers are no longer just research tools—they are central to how healthcare will be delivered, tailored and optimized in the U.S.

In sum, the U.S. biomarkers market is not simply expanding—it is transforming healthcare infrastructure, reshaping how disease is detected, managed and prevented. Those who anticipate the next frontier of biomarker innovation will help define the next chapter of personalized medicine.

More Trending Latest Reports By Polaris Market Research:

Filter Bags Market

Industrial Refrigeration Systems Market

Web Real-Time Communication (WebRTC) Market

Lithium-Sulfur Battery Market

Industrial Refrigeration Systems Market

Cognitive Computing Market

Sensitive Toothpaste Market

Amaranth Market

Enzymatic DNA Synthesis Market